![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by PeterMartin on May 7, 2018, at 15:51:26
I'd be interested in trying this although I'm sure it'll be extremely expensive whenever available. Article: https://www.empr.com/news/esketamine-nasal-spray-treatment-resistant-depression-elderly/article/763942/
Phase 3:
-
Positive Results Announced for Esketamine in Treatment-Resistant DepressionFirst-of-its-kind study conducted in elderly patients with treatment-resistant depression
First-of-its-kind study conducted in elderly patients with treatment-resistant depression
Janssen announced positive results from two Phase 3 studies evaluating esketamine nasal spray in patients with treatment-resistant depression (defined as patients who have not responded to ≥2 antidepressants of adequate dose and duration in the current episode of depression). In both studies, the primary efficacy endpoint was change from baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.In a study evaluating adults with treatment-resistant depression (N=223), flexibly dosed esketamine nasal spray (56mg or 84mg) added to a newly initiated oral antidepressant was associated with a statistically significant, clinically meaningful rapid reduction of depressive symptoms vs placebo nasal spray plus a newly initiated oral antidepressant (least squares [LS] mean difference -4.0, 95% CI: -7.31, -0.64; P =.010).
A second study in elderly patients (≥65 years) with treatment-resistant depression (N=138) found that flexibly dosed esketamine nasal spray (28mg, 56mg or 84mg) added to a newly initiated oral antidepressant led to clinically meaningful effects vs placebo nasal spray plus a newly initiated oral antidepressant (median unbiased estimate of difference from placebo -3.6, 95% CI: -7.20, 0.07; P =.029), however, the study did not reach statistical significance for its primary efficacy endpoint.
Posted by SLS on May 7, 2018, at 21:16:54
In reply to Positive Results Announced for Esketamine in TRD, posted by PeterMartin on May 7, 2018, at 15:51:26
Does esketamine have the potential to produce dissociation and psychosis? These things are problems with ketamine.
Hopefully, researchers will take a second look at hydroxynorketamine (HNK). It is a metabolite of ketamine that can be taken orally, and doesn't cause dissociation or psychosis.
- Scott
Posted by rjlockhart37 on May 7, 2018, at 23:55:10
In reply to Re: Positive Results Announced for Esketamine in TRD, posted by SLS on May 7, 2018, at 21:16:54
esketamine is almost the same thing as ketamine i will probably never take it in my life time, but i've heard positive reviews of it for depression.....but its hard to think because the ketamintine class is a dissociative drug, you kinda go out of grid, and have that spiritual feelings something with connecting with the universe
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.